SARS-CoV-2-IN-8 is a SARS-CoV-2 main protease inhibitor with an IC50 value of 0.75 μM.

SARS-CoV-2-IN-6 is a SARS-CoV-2 3CLpro inhibitor that shows the most potent enzyme inhibitory IC50 value of 73 nM.

SARS-CoV-2-IN-7 inhibits viral replication with a nanomolar IC50 value (844 nM) in SARS-CoV-2-infected Vero E6 cells.

NK007 is a novel anti-SARS-CoV-2 agent with an EC50 value of 30 nM.

SARS-CoV-2-IN-9 is an inhibitor binding to subsites S1 and S2 in SARS-CoV-2 main protease.

Cichoriin is an active compounds against SARS-CoV-2, and may be a potential candidate in treating severe COVID-19.

HeE1-2Tyr, a pyridobenzothiazole compound, is a flavivirus RNA dependent RNA polymerases (RdRp) inhibitor. HeE1-2Tyr significantly inhibits West Nile, Dengue and SARS-CoV-2 RdRps (IC50 of 27.6 µM) activity in vitro.

Lufotrelvir (PF-07304814), a phosphate prodrug of PF-00835231, acts as a potent 3CLpro protease (Mpro) inhibitor with SARS-CoV-2 antiviral activity. Lufotrelvir binds and inhibits SARS-CoV-2 3CLpro activity with a Ki of 174nM. Lufotrelvir is promising single antiviral agent and also can be used for the research of combination with other antivirals that target other critical stages of the coronavirus life cycle.

RdRP-IN-2 is a RNA dependent RNA polymerase (RdRp) inhibitor. RdRP-IN-2 significantly inhibits SARS-CoV-2 RdRp with an IC50 of 41.2 µM.RdRP-IN-2 also inhibits Feline coronavirus (FIPV) replication.

Guanosine triphosphate is a native nucleotide. The derivatives of GTP may be used as specific inhibitors against COVID-19.

(Rac)-X77 is a racemate of X77. X77 is a potent non-covalent inhibitor of the main protease of SARS-CoV-2 (SARS-CoV-2 Mpro). X77 binds to SARS-CoV-2 Mpro with a Kd value of 0.057 μM.

Hispidulin 4'-O-β-D-glucopyranosid, a natural compound, may serve as a potential COVID-19 main protease inhibitor.

Cleistanthin B (Diphyllin O-glucoside) is an orally active arylnaphthalene lignan lactone glycoside. Cleistanthin B exhibits anti-SARS-CoV-2 effects in Vero cells, with EC50 of 6.51 µM. Cleistanthin B also exhibits antitumor, diuretic and antihypertensive effects in vivo.

AT-9010 triethylamine, a triphosphate active metabolite of AT-527, is a potent inhibitor of NiRAN (a function essential for viral replication). AT-9010 triethylamine can inhibit SARS-CoV-2 replication.

AT-9010 tetrasodium, a triphosphate active metabolite of AT-527, is a potent inhibitor of NiRAN (a function essential for viral replication). AT-9010 tetrasodium can inhibit SARS-CoV-2 replication.

AT-9010, a triphosphate active metabolite of AT-527, is a potent inhibitor of NiRAN (a function essential for viral replication). AT-9010 can inhibit SARS-CoV-2 replication.

GRL-0496 is a potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitor, with an IC50 of 30 nM in both enzyme inhibitory and antiviral assays. GRL-0496 shows SARS-CoV antiviral activity, with an EC50 of 6.9 μM.

Jun8-76-3A is a potent and selective noncovalent SARS-CoV-2 Mpro inhibitor with Ki of 0.07 μM. Jun8-76-3A only selectively inhibits SARS-CoV-2 and SARS-CoV Mpro, but not other viral proteases and host proteases including calpain 1, cathepsins L and K, and trypsin.

X77 is a potent inhibitor of the main protease of SARS-CoV-2 (SARS-CoV-2 Mpro).

Aviptadil acetate is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil acetate induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil acetate can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al.

Bonducellpin D is a furanoditerpenoid lactone isolated from Caesalpinia minax. Bonducellpin D exhibits broad-spectrum inhibition potential against SARS-CoV Mpro and MERS-CoV Mpro, with an Ki of 467.11 and 284.86 nM, respectively. Bonducellpin D also exhibits moderate anti-cancer activity in vitro.

Mpro inhibitor N3 hemihydrate is a potent inhibitor of SARS-CoV-2 Mpro with an EC50 of 16.77 μM for SARS-CoV-2. Mpro inhibitor N3 hemihydrate specifically inhibits Mpro from multiple coronaviruses, including SARS-CoV and MERS-CoV. Mpro inhibitor N3 hemihydrate displays inhibition against HCoV-229E, FIPV, and MHV-A59 with individual IC50 of 4.0 μM, 8.8 μM, and 2.7 μM, respectively.

TH1217 (ZINC1775962367) is a potent and selective dCTPase pyrophosphatase 1 (dCTPase) inhibitor, with an IC50 of 47 nM. TH1217 enhances the cytotoxic effect of cytidine analogues in leukemia cells. TH1217 also could modulate SARS-Cov-2 interactors, so it shows activity of against COVID-19.

(±)-Alliin is the main active component of garlic. (±)-Alliin is a putative inhibitor of the main protease of SARS-CoV-2 (Mpro).

NHC-triphosphate is an intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) as a triphosphate form. NHC-triphosphate is a weak alternative substrate for the viral polymerase and changes the mobility of the product in polyacrylamide electrophoresis gels[1].

This pool is delivered in subpools of 291 peptides derived from a peptide scan through the entire Spike glycoprotein (Protein ID: P15423) of Human coronavirus 229E (HCoV-229E) for T cell assays. 5mg per peptide, purity>95% Total Length: 1173 AA; Sequence: MFVLLVAYAL LHIAGCQTTN GLNTSYSVCN GCVGYSENVF AVESGGYIPS DFAFNNWFLL TNTSSVVDGV VRSFQPLLLN CLWSVSGLRF TTGFVYFNGT GRGDCKGFSS DVLSDVIRYN LNFEENLRRG TILFKTSYGV VVFYCTNNTL VSGDAHIPFG TVLGNFYCFV NTTIGNETTS AFVGALPKTV REFVISRTGH FYINGYRYFT LGNVEAVNFN VTTAETTDFC TVALASYADV LVNVSQTSIA NIIYCNSVIN RLRCDQLSFD VPDGFYSTSP IQSVELPVSI VSLPVYHKHT FIVLYVDFKP QSGGGKCFNC YPAGVNITLA NFNETKGPLC VDTSHFTTKY VAVYANVGRW SASINTGNCP FSFGKVNNFV KFGSVCFSLK DIPGGCAMPI VANWAYSKYY TIGSLYVSWS DGDGITGVPQ PVEGVSSFMN VTLDKCTKYN IYDVSGVGVI RVSNDTFLNG ITYTSTSGNL LGFKDVTKGT IYSITPCNPP DQLVVYQQAV VGAMLSENFT SYGFSNVVEL PKFFYASNGT YNCTDAVLTY SSFGVCADGS IIAVQPRNVS YDSVSAIVTA NLSIPSNWTT SVQVEYLQIT STPIVVDCST YVCNGNVRCV ELLKQYTSAC KTIEDALRNS ARLESADVSE MLTFDKKAFT LANVSSFGDY NLSSVIPSLP TSGSRVAGRS AIEDILFSKL VTSGLGTVDA DYKKCTKGLS IADLACAQYY NGIMVLPGVA DAERMAMYTG SLIGGIALGG LTSAVSIPFS LAIQARLNYV ALQTDVLQEN QKILAASFNK AMTNIVDAFT GVNDAITQTS QALQTVATAL NKIQDVVNQQ GNSLNHLTSQ LRQNFQAISS SIQAIYDRLD TIQADQQVDR LITGRLAALN VFVSHTLTKY TEVRASRQLA QQKVNECVKS QSKRYGFCGN GTHIFSIVNA APEGLVFLHT VLLPTQYKDV EAWSGLCVDG TNGYVLRQPN LALYKEGNYY RITSRIMFEP RIPTMADFVQ IENCNVTFVN ISRSELQTIV PEYIDVNKTL QELSYKLPNY TVPDLVVEQY NQTILNLTSE ISTLENKSAE LNYTVQKLQT LIDNINSTLV DLKWLNRVET YIKWPWWVWL CISVVLIFVV SMLLLCCCST GCCGFFSCFA SSIRGCCEST KLPYYDVEKI HIQ

LCB-1 is a designed antiviral protein inhibiting SARS-CoV-2. LCB1 is roughly six times more potent on a per mass basis than the most effective monoclonal antibodies reported thus far.LCB1 is currently being evaluated in rodents. LCB1 binds the Spike receptor binding domain (RBD) with affinity below 1 nM and blocks ARS-CoV-2 infection of Vero E6 cells with IC50 of 23.54 pM.